An interesting study. I'm hopeful!
Abstract P1-12-15: Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in post-menopausal women
Clinical rationale: A significant proportion of post-menopausal, patients treated with AI reports side-effects, especially bone pain. In such patients, the difficulties to treat pain and to clearly identify its causes may lead to treatment discontinuation. Individual cases reported an improvement in AI tolerance when dosage is reduced. The aim of this work was thus to analyse pharmacological data in order to validate this concept ie. ensuring that intermittent dosing would not result in a possibly deleterious under-dosing of AI.
Continue reading:
https://aacrjournals.org/cancerres/article/75/9_Supplement/P1-12-15/606865/Abstract-P1-12-15-Intermittent-dosing-of-aromatase